Pradaxa was approved by the FDA in October 2010 as an anticoagulant drug designed to prevent blood clots in patients with atrial fibrillation. From the time that Pradaxa was approved the threat of a Pradaxa GI bleed was known.
In Boehringer Ingelheim Pharmaceuticals, Inc’s press release announcing the approval of Pradaxa the company acknowledges that Pradaxa 150 mg led to higher rate of gastrointestinal bleeds than Warafin. If you take Pradaxa then it is important to talk to your doctor about the potential danger of gastrointestinal bleeding. Pradaxa users should be aware of the potential symptoms of a GI bleed which may include:
- Vomiting blood.
- Bloody bowel movements.
- Black tarry looking stool.
- Abdominal pain.
- Fatigue.
- Anemia.
If you are experiencing any of these symptoms, then please consult your doctor about a potential Pradaxa GI bleed and appropriate medical treatment for your condition.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.